• Article highlight
  • Article tables
  • Article images

Article History

Received : 13-06-2024

Accepted : 01-07-2024



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 332

PDF Downloaded: 146


Get Permission Patole, Bendale, Pathan, Narkhede, Revar, and Jadhav: Dissolution method development and validation of brexpiprazole


Introduction

Figure 0
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/6a63475e-6c60-400f-8a98-a5c588bac2dbimage1.png

Brexpiprazole is a BCS class II type called (7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl] butoxy} quinoline-2(1H)-one is a new medication in psychiatric1, 2 and also in the treatment of depression which has a high affinity for monoamine neurotransmitters like serotonin, dopamine, and noradrenaline receptors, For other major depressive disorder like Alzheimer’s disease, schizophrenia3, 4, neurobehavioral disorders5, combat disorder, bipolar disorder treatment, adjunctive treatment it is mostly used. It has more potency than other antipsychotic drugs with little aqueous solubility and substantial intestinal permeability.6, 7

Figure 1

Structure of Brexpiprazole 8

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/6a63475e-6c60-400f-8a98-a5c588bac2dbimage2.png

Brexpiprazole was originally approved in the United States in July 2015 for use as an adjunctive action for major depressive disorder (MDD) and schizophrenia.9 Antipsychotics are first and second-generation drugs that are mainly active as D2 receptor antagonists.10, 11 Brexpiprazole acts as a partial agonist of the serotonin 5-HT1A receptor and the dopamine D2 and D3 receptors. Partial agonists have both blocking properties and stimulating properties at the receptor they bind to. The ratio of blocking activity to stimulating activity determines a portion of its clinical effects. .12 brexpiprazole is a substrate of CYP2D6 and CYP3A4, like its predecessor aripiprazole. Participants in the clinical trials are advised to avoid grapefruit, Seville oranges and related citruses. The literature survey discovered that by UV-visible spectroscopy and HPLC.13, 14, 15, 16, 17 method Brexpiprazole was determined. In the current work, the authors have proposed dissolution method development and validation of Brexpiprazole which is a simple, precise, robust, and valid RP-HPLC method for the estimation of Brexpiprazole in the pharmaceutical active dosage form.

Materials and Methods

Chemicals and solvents

Brexpiprazole standard (Purity ≥ 99.7), triethylamine, phosphoric acid, Methanol, HPLC grade water (Millipore).

Instrumentation

The instrument employed in the present work were analytical microbalance (Make: Mettler Toledo, Model: XP56), 1260 Infinity HPLC having column Hemochrom C-8, 25 cm X 4.6 mm x 5 µ, USP Apparatus Type II (Paddle), sonicator (Make: Elma, Model: S300H),

Method development

Optimization of the chromatographic conditions

The system used was Agilent 1260 Infinity HPLC having column Hemochrom, mobile phase was prepared by a combination of 20 ml of triethylamine with 1000 ml of HPLC grade water and 680 ml of HPLC Grade Methanol. pH was adjusted to 4.0 ± 0.05 with phosphoric acid, degassed by sonicator, and mix well. The diluent used was water. Analysis was carried out at wavelength 227 nm, flow rate 1ml per minute, 18-22 °C temperature, with an injection volume of 50 µl with time 21 minutes.

Preparation of working standards

The standard solution of Brexpiprazole prepared as 27.5 mg of pure drug was dissolved in a 250 mL volumetric flask and diluted to volume with water. Further 10 mL of stock was diluted to 50 mL with diluent, further, dilute 5 ml of the above-diluted solution to 10 ml with diluent.

Method validation

By analyzing linearity, precision (method and intermediate), accuracy, LOD, LOQ, deterioration, and robustness, the present created technique was verified according to ICH and FDA requirements.

Specificity

Specificity is the ability to access unequivocally the analyte in the presence of components that may be expected to be present. Separate vials were prepared and injected to check the interference. The standard solution was prepared to have a percentage purity of 99.61%. The analysis was done using various methods such as Blank solution, Control standard solution, Test solution and Placebo solution respectively.

Accuracy

Accuracy was conducted in the range of 20 % to 150 % of working concentration of 10 mg strength. Solutions of each accuracy level were prepared in triplicate. The study was performed by using placebo tablets of 10 mg strength. Determination of percent recovery was carried out in each study.

Linearity and range

The linearity parameter of an analytical procedure is its ability to obtain test results that are directly proportionally to the concentration of analyte in the sample. Linearity was conducted for the Brexpiprazole concentration between 20% to 150% level of limit concentration. Graphically region was plotted. The range was evaluated based on linearity.

Precision

Precision was conducted by using tablets of 10.0 mg strength. This study was performed on 6 different jars. Standard solutions were prepared by purity 99.61%, Weight 27.69mg, and Concentration 11.03 µg/ml. In the precision determination method, the blank and standard solution method was used, also the intermediate precision determination method was done by using standard and blank solution.18

Robustness

The robustness was performed by using different samples with chromatogram injection and check the parameter to carrying out deliberate variations like Flow rate (±10%), Wavelength (+10 % at 230 nm and -10 % at 224 nm), RPM (±10%) and the volume of the dissolution medium (changed by ±10%)

Table 1

Method parameters of HPLC for robustness

Sr. No.

Parameter

Actual Parameter

Parameter to be changed

1

HPLC (Flow Rate)

1.000 ml

0.900 ml

1.100 ml

2

HPLC (Wavelength)

227 nm

224 nm

230 nm

3

Dissolution apparatus: RPM

75

68

82

4

Dissolution apparatus: Volume of Dissolution Medium

900 ml

890 ml

910 ml

Results

Method development

The developed chromatographic conditions were optimized to determine Brexpiprazole in drug substance and dosage form. The symmetrical peak was found with Hemochrom C-8, 25 cm X 4.6 mm x 5 µ or equivalent column at 18-22 °C, and the mobile phase consisted of 20 ml of Triethylamine with 1000 ml of HPLC grade water and 680 ml of HPLC Grade Methanol. Adjust the pH of this solution to 4.0 ± 0.05 with phosphoric acid. Detector performed at 227 nm and the flow rate was 1.0 mL/min. The injection volume was 50 µl and the run time was 25 min.

Specificity

The developed chromatographic method passed specificity criteria and the results of specificity are given the table 2-3.

Table 2

Summary of results for specificity study

Sr. No.

Solution Name

Area

% Interference

Remark

1

Blank

ND

NA

NA

2

Control standard

13785046

99.4

Due to Brexpiprazole

3

Calibration standard

13874561

100.0

Due to Brexpiprazole

4

Placebo solution

ND

NA

NA

5

Drug substance

13963158

100.6

Due to Brexpiprazole

6

Drug substance + Placebo

13930289

100.4

Due to Brexpiprazole

7

Test solution

13877334

100.0

Due to Brexpiprazole

ND-

Table 3

Result of specificity

Sr. No.

Evaluation parameter

Results

Acceptance Criteria

1.

Specificity

Retention time of Brexpiprazole peak in the test solution is comparable to that in standard solution.

Retention time of Brexpiprazole peak in test solution should be comparable to that in standard solution.

Interference of diluent and placebo is not more than 0.5% of Brexpiprazole

Interference of diluent and placebo should not be more than 0.5% of Brexpiprazole

Accuracy

The accuracy was done by analyzing samples at six different levels of concentrations the recovery of the method was determined by spiking Brexpiprazole active substances. The % recovery results are shown in table 4-5.

Table 4

Accuracy levels area response

Levels

% Level w.r.t. working concentration

The concentration of levels in µg/mL

Area

Added Concentration in µg/mL

Recovered Concentration in µg/mL

% Recovery (Rounded)

1

20

2.20

2819899

2.20

2.16

98.0

2.20

2804934

2.20

2.14

97.0

2.20

2820437

2.20

2.16

98.0

2

50

5.50

6964933

5.50

5.32

97.0

5.50

6989944

5.50

5.34

97.0

5.50

6985517

5.50

5.34

97.0

3

75

8.25

10499850

8.25

8.03

97.0

8.25

10509541

8.25

8.03

97.0

8.25

10514228

8.25

8.04

98.0

4

100

11.00

14260907

11.00

10.90

99.0

11.00

14336655

11.00

10.96

100.0

11.00

14359693

11.00

10.98

100.0

5

125

13.76

17818661

13.76

13.62

99.0

13.76

17820402

13.76

13.62

99.0

13.76

17814170

13.76

13.62

99.0

6

150

16.51

21328801

16.51

16.31

99.0

16.51

21329407

16.51

16.31

99.0

16.51

21239906

16.51

16.24

98.0

Average % Recovery

98.2

Standard Deviation

1.0603

Relative standard Deviation

1.1

Minimum % Recovery

97.0

Maximum % Recovery

100.0

Sample size

18

Confidence Coefficient

1.96

Margin of error

0.4898

95% Confidence interval upper limit

98.7

95% Confidence interval lower limit

97.7

95% Confidence interval

97.7-98.7

Table 5

Accuracy results

Sr. No.

Evaluation Parameter

Results

Acceptance Criteria

1

Individual % Recovery

Between 97.0% to 100.0%

Between 95.0% and 105.0%

2

Mean % recovery (n=18)

98.2

Between 97.0% and 103.0%

3

95 % Confidence Interval

97.7 - 98.7

To be reported

Linearity

Linearity was conducted for the Brexpiprazole concentration between 20% to 150% level of limit concentration. Range was evaluated based on linearity. Linearity summary is given in the graph is in figure 2 and in table from 6.

Figure 2

Linearity graph ofBrexpiprazol

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/6a63475e-6c60-400f-8a98-a5c588bac2dbimage3.png
Table 6

Linearity and range results

Sr. No.

Evaluation Parameter

Results

Acceptance criteria

1

Correlation Coefficient

0.999

≥ 0.99

2

Y – Intercept

-99954.1606

To be reported

3

% Y – Intercept

-0.7

≤ ± 5

4

Slope of regression line

1299178.9578

To be reported

6

Residual sum of square

40291650086

To be reported

7

Range

2.20 to 16.51

To be reported

Precision

The Method precision and Intermediate precision (ruggedness) were prepared and evaluated six samples at 100% of the target sample concentration as per the method. The results of % assay and % RSD are presented in Table 7-9 and in figure 3.

Method Prescision

Table 7

Observation summary of test solution

Test

Retention time

Area

%Drug released

1

17.82

14132702

99.10

2

17.83

14135590

99.12

3

17.82

14167535

99.35

4

17.79

14062104

98.61

5

17.81

14090551

98.81

6

17.83

14254142

99.96

Average

17.817

14140437.333

99.158

SD

0.0151

66889.6467

0.4691

% RSD

0.08

0.47

0.47

Table 8

System suitability test for precision study

Sr. No.

Evaluation Parameter

Results

Acceptance Criteria

1

% Recovery of control standard against average Calibration standard.

101.2

Between 98.0% and 102.0%

2

% Recovery of bracketing / closing standard against average calibration standard.

99.7

Between 98.0% and 102.0%

3

% RSD of minimum 5 replicate injections of the calibration standard.

0.09

NMT 2.0 %

Table 9

Observation summary of test solution

Test

Retention time

Area

% Drug released

1

17.81

13881294

98.44

2

17.82

13907429

98.63

3

17.8

13799749

97.86

4

17.81

13896722

98.55

5

17.81

13854417

98.25

6

17.81

13871104

98.37

Average

17.810

13868452.500

98.352

SD

0.0063

38490.0843

0.2730

% RSD

0.04

0.28

0.28

Figure 3

Intermediate precision results

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/6a63475e-6c60-400f-8a98-a5c588bac2dbimage4.png

Robustness

The robustness of the method was studied by small variation of the chromatographic conditions such as flow (1.0 ± 0.2 mL/min), column temperature (30 ± 5°C), and mobile phase composition (±10% absolute). The results are given in Table 10-16.

Table 10

Sr. No.

Parameter

Actual Parameter

Parameter to be changed

1

HPLC (Flow Rate)

1.000 ml

0.900 ml

1.100 ml

2

HPLC (Wavelength)

227 nm

224 nm

230 nm

3

Dissolution apparatus: RPM

75

68

82

4

Dissolution apparatus Volume of Dissolution Medium

900 ml

890 ml

910 ml

Table 11

Parameters ofrobustness

Test

Retention time

Area

% Drug released

1

16.96

13302656

99.13

2

16.95

13219849

98.51

3

16.95

13250240

98.74

4

16.95

13266822

98.86

5

16.95

13243665

98.69

6

16.96

13229258

98.58

Average

16.953

13252081.667

98.752

SD

0.0052

29695.5794

0.2221

% RSD

0.03

0.22

0.22

Table 12

Observation summary of test solution for change in flow rate (+10%)

Test

Retention time

Area

% Drug released

1

18.82

15179637

98.93

2

18.83

15161521

98.81

3

18.82

15182428

98.95

4

18.82

15183974

98.96

5

18.81

15163972

98.83

6

18.82

15189733

98.99

Average

18.820

15176877.500

98.911

SD

0.0063

11457.9327

0.0747

% RSD

0.03

0.08

0.08

Table 13

Observation summary of test solution for change in flow rate (-10%)

Test

Retention time

Area

% Drug released

1

17.72

10558518

98.94

2

17.72

10548074

98.84

3

17.72

10566387

99.01

4

17.73

10553938

98.89

5

17.72

10561257

98.96

6

17.72

10563592

98.98

Average

17.722

10558627.667

98.937

SD

0.0041

6707.4416

0.0622

% RSD

0.02

0.06

0.06

Table 14

Observation summary of test solution for change in wavelength (+10%)

Test

Retention time

Area

% Drug released

1

17.72

14654726

98.55

2

17.72

14635423

98.42

3

17.72

14642595

98.47

4

17.73

14665109

98.62

5

17.73

14655124

98.55

6

17.73

14654220

98.54

Average

17.725

14651199.500

98.525

SD

0.0055

10520.1795

0.0701

% RSD

0.03

0.07

0.07

Table 15

Observation summary of test solution for change in flow rate (-10%)

Test

Retention time

Area

% Drug released

1

18.02

14318703

99.69

2

17.97

14248589

99.20

3

17.98

14234946

99.11

4

17.97

14195429

98.83

5

17.97

14161434

98.60

6

17.98

14220280

99.01

Average

17.982

14229896.833

99.073

SD

0.0194

53346.2295

0.3701

% RSD

0.11

0.37

0.37

Table 16

Observation summary of test solution for change in RPM (+10%)

Test

Retention time

Area

% Drug released

1

17.97

14254419

99.25

2

17.97

14208519

98.93

3

17.98

14256434

99.26

4

17.97

14217491

98.99

5

17.98

14234364

99.11

6

17.95

14216445

98.98

Average

17.970

14231278.667

99.087

SD

0.0110

20522.7920

0.1432

% RSD

0.06

0.14

0.14

Change in Rpm – Dissolution Apparatus

Table 17

Observation summary of test solution for change in volume of dissolution medium (+10%)

Test

Retention time

Area

% Drug released

1

17.97

14174713

98.62

2

17.97

14217690

98.92

3

17.98

14193228

98.75

4

17.98

14183120

98.68

5

17.99

14118944

98.23

6

17.99

14141478

98.39

Average

17.980

14171528.833

98.598

SD

0.0089

35817.3659

0.2501

% RSD

0.05

0.25

0.25

Table 18

Observation summary of test solution for change in volume of dissolution medium (-10%)

Test

Retention time

Area

% Drug released

1

17.96

14154612

98.48

2

17.97

14166845

98.57

3

17.97

14158635

98.51

4

17.97

14152137

98.46

5

17.97

14124843

98.27

6

17.97

14161002

98.52

Average

17.968

14153012.333

98.468

SD

0.0041

14721.6052

0.1042

% RSD

0.02

0.10

0.11

Discussion

In this RP-HPLC method, the Retention time of the Brexpiprazole peak in the test solution is comparable to that in the standard solution. It was found that interference of diluent and placebo is not more than 0.5% of Brexpiprazole. The individual % recovery was found to be between 97.0% to 100.0%, the linearity was within the range of 10- 60 µg mL with a Correlation Coefficient of 0.999, Slope of the regression line was found to be 1299178.9578 which means all parameters were found to be within range. In precision % RSD for % released dissolution values were found to be 99.16, in robustness, all the parameters like change in the flow rate, wavelength, and in RPM shows that the developed method was robust.

Conclusion

This study is a stability-indicating analysis that was done in accordance with ICH/FDA criteria. The proposed approach performed well in terms of sensitivity, precision, accuracy, linearity and range, robustness. The well-known RP-HPLC method for the study of Brexpiprazole was shown to be trustworthy, as well as easy, consistent, cost-effective, and exact. For quality control or routine quantification, this method is applicable to determine Brexpiprazole in a bulk and pharmaceutical dosage form. This developed method required less time.

Abbreviations

RP-HPLC- Reversed-phase high-performance liquid chromatography, USP- United States Pharmacopeia, LOD- Limit of detection LOQ- Limit of quantification, D2- Dopamine receptor, ICH- International Council on Harmonisation, FDA- Food drug administration, RPM-Rotation per minute, ND- Not detected, NA- Not applicable, RSD- Relative standard deviation.

Source of Funding

None.

Conflict of Interest

None.

References

1 

AS Jagdale NS Pendbhaje RV Nirmal PM Bachhav DB Sumbre Development and validation of RP-HPLC method for estimation of brexpiprazole in its bulk and tablet dosage form using Quality by Design approachFuture J Pharm Sci20217142

2 

G Jones Brexpiprazole: a review in schizophreniaCNS Drugs201630433577

3 

J D Croxtall Aripiprazole: a review of its use in the management of schizophrenia in adultsCNS Drugs201226215583

4 

J Mcevoy L Citrome Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity ModulatorClin Schizophr Relat Psychoses20169417786

5 

L Citrome Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorderDrugs Today (Barc)2015517397414

6 

K Maeda H Sugino H Akazawa AN Shimada Brexpiprazole I: In Vitro and In Vivo Characterization of a Novel Serotonin-Dopamine Activity ModulatorJ Pharm Experim Therap20143503589604

7 

L Citrome J Volavka Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine to CariprazineHarvard Rev Psych20212912034

8 

M Ma Q Ren C Yang Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: Role of BDNF-TrkB signalingSci Rep2016639209

9 

J Enders SG Reddy EC Strickland GL Mcintire Identification of metabolites of brexpiprazole in human urine for use in monitoring patient compliance.Clin Mass Spectro20176214

10 

SL Greig Brexpiprazole: first global approvalDrugs20157514168797

11 

K Maeda H Sugino H Akazawa Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulatorJ Pharmacol Exp Ther20143503589604

12 

CA Oosterhof El Mansari M Blier Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterizationJ Pharmacol Exp Ther2014351358595

13 

AM Thakkar UK Chhalotiya N Parekh JV Desai HB Dalwadi DA Shah Quantification of Brexpiprazole in bulk and its pharmaceutical dosage form by UV-visible spectroscopic and SIAM RP-LC methodAustin Chromatogr20185150

14 

A Sravani N Durga CH Uppalapati D Suneetha CH Suresh P Tirumaleswara Method development and validation for the estimation of Brexpiprazole in drug substance By RP-HPLC methodIndo Am J Pharm Res2017785605

15 

PB Nehal BP Ashok MS Rao JV Amit KP Nilesh P Ajay Development and validation of stability-indicating assay method and characterization of degradation product for Brexpiprazole bulk by RP-HPLCJ Chem Pharm Res20181015566

16 

B Sowjanya K Rambabu Development and validation for the simultaneous estimation of Brexpiprazole and fluoxetine in drug substance by RP-HPLCEuro J Biomed Pharm Sci201854117

17 

G Amit P Rajendra Gradient high-performance liquid chromatography method for determination of related substances in Brexpiprazole APIInt J Dev Res201882141624

18 

R Shah A Nagar R Bardiya A Shirkhedkar D Purohit A Bendale Combined and comparative analytical studies with stability studies and validation for estimation of prenoxdiazine HCl in pharmaceutical dosage formFuture J Pharma Sci20239153



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.